116 related articles for article (PubMed ID: 12460783)
1. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
Sessa C; Weigang-Köhler K; Pagani O; Greim G; Mora O; De Pas T; Burgess M; Weimer I; Johnson R
Eur J Cancer; 2002 Dec; 38(18):2388-96. PubMed ID: 12460783
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
D'Agostino G; del Campo J; Mellado B; Izquierdo MA; Minarik T; Cirri L; Marini L; Perez-Gracia JL; Scambia G
Int J Gynecol Cancer; 2006; 16(1):71-6. PubMed ID: 16445613
[TBL] [Abstract][Full Text] [Related]
4. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Edelman MJ; Gandara DR; Hausner P; Israel V; Thornton D; DeSanto J; Doyle LA
Lung Cancer; 2003 Feb; 39(2):197-9. PubMed ID: 12581573
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.
Mita AC; Hammond LA; Bonate PL; Weiss G; McCreery H; Syed S; Garrison M; Chu QS; DeBono JS; Jones CB; Weitman S; Rowinsky EK
Clin Cancer Res; 2006 Sep; 12(17):5207-15. PubMed ID: 16951240
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
[TBL] [Abstract][Full Text] [Related]
19. An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
Awada A; Thödtmann R; Piccart MJ; Wanders J; Schrijvers AH; Von Broen IM; Hanauske AR;
Eur J Cancer; 2003 Apr; 39(6):742-7. PubMed ID: 12651198
[TBL] [Abstract][Full Text] [Related]
20. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703.
De Pas TM; Mandalà M; Curigliano G; Peccatori F
Obstet Gynecol; 2000 Jun; 95(6 Pt 2):1030. PubMed ID: 10808018
[No Abstract] [Full Text] [Related]
[Next] [New Search]
